Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer

Volume: 379, Issue: 21, Pages: 2027 - 2039
Published: Sep 25, 2018
Abstract
Background Brigatinib, a next-generation anaplastic lymphoma kinase (ALK) inhibitor, has robust efficacy in patients with ALK-positive non–small-cell lung cancer (NSCLC) that is refractory to crizotinib. The efficacy of brigatinib, as compared with crizotinib, in patients with advanced ALK-positive NSCLC who have not previously received an ALK inhibitor is unclear. Methods In an open-label, phase 3 trial, we randomly assigned, in a 1:1 ratio,...
Paper Details
Title
Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer
Published Date
Sep 25, 2018
Volume
379
Issue
21
Pages
2027 - 2039
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.